These observations were consistent with the rescue of PB counts seen in Figure 6B. Taken together, TFD-driven aggressive AML responds to a combination therapy that targets the mutated receptor tyrosine kinase, epigenetic changes due to Tet2 and Dnmt3a mutations, and inflammation caused by the presence of genetic and epigenetic mutations. Here, DNMT3A is linked to acute myeloid leukemia.